Overview of the impact of conventional systemic therapies on breast cancer

被引：12
|
作者：
Howell, A [1 ]
Wardley, AM [1 ]
机构：
[1] Univ Manchester, Christie Hosp, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England
来源：
ENDOCRINE-RELATED CANCER | 2005年 / 12卷
关键词：
D O I：
10.1677/erc.1.01003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Survival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.
引用
收藏
页码：S9 / S16
页数：8
相关论文
共 50 条
  • [41] SYSTEMIC THERAPY FOR INOPERABLE LOCALLY ADVANCED BREAST CANCER: OPTIMAL STRATEGIES AND THERAPIES
    Harbeck, Nadia
    Wuerstlein, Rachel
    BREAST, 2013, 22 : S21 - S21
  • [42] USE OF COMPLEMENTARY THERAPIES IN BREAST AND GYNAECOLOGICAL CANCER PATIENTS DURING SYSTEMIC THERAPY
    Drozdoff, L.
    Klein, E.
    Gantner, L.
    Kiechle, M.
    Paepke, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 107 - 107
  • [43] Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy
    Roila, F
    Ballatori, E
    Patoia, L
    Palazzo, S
    Veronesi, A
    Frassoldati, A
    Cetto, G
    Cinieri, S
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2003, 14 (06) : 843 - 848
  • [44] Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era
    Colozzaa, Mariantonietta
    de Azambuja, Evandro
    Cardoso, Fatima
    Bernard, Chantal
    Piccart, Martine J.
    ONCOLOGIST, 2006, 11 (02): : 111 - 125
  • [45] USE OF COMPLEMENTARY THERAPIES IN BREAST AND GYNAECOLOGICAL CANCER PATIENTS DURING SYSTEMIC THERAPY
    Drozdoff, L.
    Klein, E.
    Gantner, L.
    Kiechle, M.
    Paepke, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 611 - 611
  • [46] Adjuvant systemic treatment for operable breast cancer standard therapies and new approaches
    Goldhirsch, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S88 - S88
  • [47] The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Robert, NJ
    Vogel, CL
    Henderson, C
    Sparano, JA
    Moore, MR
    Silverman, P
    Overmoyer, BA
    Shapiro, CL
    Park, JW
    Colbern, GT
    Winer, EP
    Gabizon, AA
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 106 - 146
  • [48] Adjuvant early breast cancer systemic therapies according to daily used technologies
    Jacot, W.
    Gutowski, M.
    Azria, D.
    Romieu, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 (03) : 361 - 369
  • [49] A longitudinal study of the neuropsychological sequelae of systemic therapies for early stage breast cancer
    Riggs, RL
    Anderson-Hanley, C
    Sherman, M
    Muss, H
    O'Brien, P
    Compas, BE
    PSYCHO-ONCOLOGY, 2003, 12 (04) : S227 - S228
  • [50] Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy
    不详
    CURRENT PROBLEMS IN CANCER, 2003, 27 (01) : 13 - 16
12345